A Phase 4 interventional study of Guideline directed statin therapy and High intensity statin plus ezetimibe therapy in Coronary Artery Calcification, Metabolic Syndrome and Dyslipidemias, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Metabolic Syndrome with a site in Korea, Republic of — 4 open to participants now, 4 under way, none of them phase 3. Metabolic Syndrome · Korea, Republic of.
Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, this one has the largest planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2023, is one of 11 in phase 4, and was the 50th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →4 of the 53 studies in Metabolic Syndrome with a site in Korea, Republic of are open now. Recruiting first, the newest first:
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
Hallym University · Sites in Korea, Republic of
Ages 20–70
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 67 across the 31 interventional studies, 150 across the 22 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 53 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Metabolic Syndrome with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.
Atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction (MI), ischemic stroke, or peripheral arterial disease, are the leading cause of morbidity and mortality worldwide. The causality of low-density lipoproteins cholesterol (LDL-C) level in the development of ASCVD is well demonstrated in previous studies. After introducing LDL-C lowering agents, multiple large-scale randomized clinical trials have demonstrated lower cardiovascular events with lowering LDL-C levels. In particular, for secondary prevention, more aggressive control of LDL-C levels with high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. In addition, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) proved the clinical efficacy of additive ezetimibe for incrementally lowering of LDL-C levels in patients with acute coronary syndrome. However, there has been limited evidence regarding the efficacy and safety of aggressive lipid-lowering strategy using high-intensity statin with a combination of ezetimibe for primary prevention of cardiovascular events among persons without cardiovascular disease. Although the Heart Outcomes Prevention Evaluation (HOPE)-3 and Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials consistently identified that the use of rosuvastatin (10 mg or 20 mg) was significantly associated with reduced future risk of major cardiovascular events in patients who did not have cardiovascular disease, those studies have been focused on the use of statin, not on the intensity of statin.
The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or ASCVD risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD to guide the use of statin or not. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk. Considering that statin has additional properties, including atherosclerotic plaque stabilization, oxidative stress reduction, enhancement of endothelial function, and a decrease in vascular inflammation beyond their lipid-lowering effect, aggressive treatment with a high-intensity statin plus ezetimibe combination might have beneficial effects on the long-term clinical outcomes for asymptomatic patients with significant coronary calcium (Agatston Score ≥ 100) compared with standard lipid-lowering therapy endorsed by the current guidelines.
Therefore, the purpose of DECISION-CALCIUM (Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM) trial is to compare the efficacy and safety of the aggressive lipid-lowering therapy with combination of high-intensity statin and ezetimibe, compared with the current standard lipid-lowering therapy in asymptomatic patients with significant coronary calcification for primary prevention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, high-intensity statin (rosuvastatin 20mg) combined with ezetimibe 10 mg will be prescribed regardless of patients' age, concomitant diabetes mellitus, or ASCVD risk.
Drug: High intensity statin plus ezetimibe therapy
In this group, lipid lowering therapy will be followed according to the current guideline recommendation. A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus. For non-diabetic patients aged 40-75 years, the use of statins will be determined by calculating the ASCVD risk score. (ASCVD risk \<7.5%: no statin use, ≥7.5 - \<20%: moderate-intensity statin \[rosuvastatin 5mg\], ≥ 20%: high-intensity statin \[rosuvastatin 20mg\])
Drug: Guideline directed statin therapy
At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
Rosuvastatin 20 mg + Ezetimibe 10 mg
Major adverse cardiovascular events
a composite of death from any causes, myocardial infarction, stroke, unplanned coronary revascularization, or other arterial revascularization procedure
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
All-cause death
Death from any causes
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Cardiovascular death
Death from cardiovascular causes
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Stroke
Ischemic or hemorrhagic stroke
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Unplanned coronary revascularization
revascularization procedure to coronary artery
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Arterial revascularization procedure
All arterial revascularization procedure
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Major bleeding
Bleeding Academic Research Consortium (BARC) type 3-5
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Bleeding
BARC type 2-5
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Heart failure hospitalization
Hospitalization due to heart failure
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Coronary calcium progression
Delta CAC
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Changes of LDL-C
Delta LDL-C
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
New-onset diabetes mellitus
Occurence of new-onset diabetes mellitus
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Hepatic disorder requiring discontinuation of statin
Occurence of hepatic disorder requiring discontinuation of statin
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
muscle-related adverse events
Occurence of muscle-related adverse events due to statin
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Proportion of patients with LDL-C < 100mg/dL
Proportion of patients with LDL-C \< 100mg/dL
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Proportion of patients with LDL-C < 70mg/dL
Proportion of patients with LDL-C \< 70mg/dL
Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2029, 71 months after the start.
Of 32 phase 4 interventional studies under Metabolic Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.